Trial · NCT07877597
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
NCT07877597, Phase 3, Not yet recruiting, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS. Trials, record NCT07877597. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877597
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
- NCT number
- NCT07877597
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 480 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Locally Advanced Colon Cancer, pMMR
- Interventions
- short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin)
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-year event-free survival | From the date of randomization until the date of first documented disease progression or toxicity during neoadjuvant therapy that prevent surgery, local regional recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months. | rate of 3-year event-free survival |
| Secondary | pathological complete response （pCR） | one month after surgery | Defined as the proportion of patients in the arm with no residual viable tumour cells in the primary lesion and lymph nodes on surgical specimens. |
| Secondary | R0 resection rate | one month after surgery | Defined as the proportion of patients in the trial arm who achieve curative resection with microscopically negative resection margins. |
| Secondary | Organ preservation rate: | one month after surgery | Defined as the proportion of patients in the trial arm without combined organ resection. |
| Secondary | 5-year overall survival | From the time of randomisation to 5 years. | Defined as the proportion of patients in the trial arm who are still alive at 5 years from randomisation. |
| Secondary | Grade ≥3 toxicity rate | From the time of randomization to 1 year after complete treatment | Defined as the proportion of all enrolled patients who experience grade 3 or higher adverse events related to radiotherapy, chemotherapy and immunotherapy during and after the combined treatment. |
| Secondary | Surgical complication rate | From the time of surgery to 1 month after surgery | Defined as the proportion of operated patients who develop surgical-related complications including wound infection, anastomotic leak, haemorrhage and others after surgery. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877597
GET https://conductscience.org/api/trials/v1/NCT07877597/registered